Patients suffering from muscular dystrophy may soon be able to independently monitor their therapeutic response to…
Articles by Margarida Azevedo, MSc
South Plainfield, NJ-based biopharmaceutical company PTC Therapeutics, Inc. recently announced that it has launched a rolling submission of a…
Stuart W. Peltz, Ph.D, the CEO of biopharmaceutical company PTC Therapeutics, Inc., was recently granted the 2014 Legend…
A trio of companies, comprised of CITGO Marketer Flash Market Inc., Core Mark and CITGO Petroleum Corporation recently hosted the…
PTC Therapeutics, Inc., a biopharmaceutical company with a focus on the discovery and development of orally administered, proprietary small…
Carlsbad, California-based Isis Pharmaceuticals, Inc. recently announced the launch of a study for ISIS-DMPKRx, indicated to treat Myotonic Dystrophy Type 1…
The Parent Project Muscular Dystrophy (PPMD), a not-for-profit organization supporting research into Duchenne muscular dystrophy (DMD)…
The Parent Project Muscular Dystrophy (PPMD) recently petitioned Congress to ask for more support in strengthening existing programs dedicated…
Encouraged by the acquisition of biotechnology company Prosensa by BioMarin Pharmaceutical, CureDuchenne has announced that it will continue to…
PTC Therapeutics, Inc. has just announced its novel protein restoration therapy Translarna™ (ataluren) is now available to…